Market Overview

Priority Review For Tetraphase's Eravacycline A 'Key Positive,' Analyst Says

Share:
Priority Review For Tetraphase's Eravacycline A 'Key Positive,' Analyst Says

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) announced Tuesday that the U.S. Food and Drug Administration accepted a New Drug Application for eravacycline, an antibiotic for complicated intra-abdominal infection, for priority review.

Traders initially reacted positively, and so did analysts.

The Rating

B Riley analyst Madhu Kumar reiterated a Buy rating on the stock with a $6 price target.

The Thesis

The NDA news is supportive of expectations for U.S. regulatory approval in the third quarter.

“We consider eravacycline receiving priority review a key positive, as the FDA gives this accelerated review process to drugs with the potential for ‘significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions when compared to standard applications,’” the analyst said in a Tuesday note. 

That acknowledged superiority would position Tetraphase to seize market share.

Eravacycline posted successful results in both the IGNITE1 and IGNITE4 Phase 3 trials, and although it failed in IGNITE3 for complicated urinary tract infection, Kumar does not expect negative read across to the intra-abdominal infection prospects.

Price Action

Tetraphase shares were trading up 6.44 percent at $2.81. 

Related Links:

The Companies That Led 2017's Biotech Rally

Pharma M&A Picks Up Momentum

Latest Ratings for TTPH

DateFirmActionFromTo
Mar 2020Gabelli & Co.DowngradesHoldSell
Jan 2020Gabelli & Co.DowngradesBuyHold
Oct 2019Gabelli & Co.UpgradesHoldBuy

View More Analyst Ratings for TTPH
View the Latest Analyst Ratings

 

Related Articles (TTPH)

View Comments and Join the Discussion!

Posted-In: B Riley eravacyclineAnalyst Color Biotech Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
BABACFRAMaintains216.0
ETNB of A SecuritiesDowngrades
HUYAB of A SecuritiesReiterates23.0
BABANomura InstinetMaintains249.0
PDDB of A SecuritiesReiterates71.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com